Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
JW0301
- Development stage
- Unknown
- Lead developer
- JW Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
**JW0301** is an investigational oral small-molecule proton-pump inhibitor developed by JW Pharmaceutical. It has been evaluated in a randomized, open-label, multiple-dose crossover Phase 1 study in healthy participants versus C2105, assessing pharmacokinetics, pharmacodynamics, safety, and tolerability. Public pipeline intelligence identifies gastroesophageal reflux disease as its intended indication. JW0301 is reported to inhibit the gastric proton pump, thereby suppressing gastric acid secretion; however, its precise chemical identity, formulation composition, commercial name, and marketed dosage strengths have not been publicly established.
02
Targets
ATP4A (Potassium–transporting ATPase alpha chain 1)
Beyond the preview
Go deeper on JW0301.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on JW0301.